Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant.

Conclusion: The T-allele carriers showed a greater reduction of cocaine use after treatment with doxazosin in participants with the ADRA1D gene polymorphism (T1848A), suggesting that this SNP may serve as a pharmacogenetic marker in pharmacotherapy of CUD.
PMID: 31914324 [PubMed - as supplied by publisher]

Source: The American Journal of Drug and Alcohol Abuse - January 7, 2020 Category: Addiction Authors: Shorter DI, Zhang X, Domingo CB, Nielsen EM, Kosten TR, Nielsen DA Tags: Am J Drug Alcohol Abuse Source Type: research